FDA Should "Raise The Bar" For NDA Supplement Exclusivity, Teva Says
FDA should maintain higher standards for awarding exclusivity for NDA supplements to prevent abuse of the Waxman-Hatch amendments by innovator firms, Teva maintained in comments on FDA's draft guidance on discontinued labeling.
You may also be interested in...
FDA is trying to head off efforts by brand name companies to extend product exclusivity through labeling changes.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials